Impaired quality of residual bone, as well as decreased bone amount, is common in patients with advanced breast cancer, and leads to skeletal complications that impair quality of life, such as bone pain and pathologic fracture. This is of increasing importance as patients live longer with metastatic disease, and is compounded by current therapies such as aromatase inhibitors. Our hypothesis is that whereas bone loss at the metastatic site is determined by osteoclast activity induced by the breast cancer cells, the quality of the residual bone at the tumor-bone interface is determined by osteoblast differentiation, which is frequently impaired in metastatic breast cancer. Furthermore, we propose that this is a consequence of ambient TGF-B concentrations which are enriched in the microenvironment of metastatic breast cancer cells in bone, and can be decreased by anti-TGFB therapy, which we hypothesize will enhance osteoblast differentiation as well as improving bone quality in bone. To test this hypothesis, we plan to investigate the specific role of TGFB in osteoblast differentiation, bone structure and quality both in patients and preclinical models of breast cancer metastasis. Preclinical models will provide important information for the design of clinical studies.
In Aim 1, we will determine the effects of impaired TGFB signaling in osteoblasts by the use of mice with conditional knockout of the TGF-B receptor kinase, and assess bone quality by state-of-the-art techniques including Raman spectroscopy, Atomic Force microscopy and uCT.
In Aim 2, we will determine the effects of anti-TGFB therapy using anti-TGF-? antibodies on bone quality, in parallel with effects on tumor burden, osteoblast differentiation and bone structure in the mice bearing human breast cancer cells, to guide the design of clinical studies in Aim 3, and provide information on the spectrum of benefits from anti-TGFB therapy.
In Aim 3, we will determine the effects of anti-TGFB antibodies on bone in a phase I study in patients with metastatic breast cancer. These studies focus on an important complication of breast cancer that markedly influences the quality of life in patients with advanced disease, and should have important therapeutic implications.
|Williams, Michelle M; Lee, Linus; Hicks, Donna J et al. (2017) Key Survival Factor, Mcl-1, Correlates with Sensitivity to Combined Bcl-2/Bcl-xL Blockade. Mol Cancer Res 15:259-268|
|Zhao, Bin; Sensintaffar, John; Bian, Zhiguo et al. (2017) Structure of a Myeloid cell leukemia-1 (Mcl-1) inhibitor bound to drug site 3 of Human Serum Albumin. Bioorg Med Chem 25:3087-3092|
|Williams, Michelle M; Vaught, David B; Joly, Meghan Morrison et al. (2017) ErbB3 drives mammary epithelial survival and differentiation during pregnancy and lactation. Breast Cancer Res 19:105|
|Jansen, Valerie M; Bhola, Neil E; Bauer, Joshua A et al. (2017) Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer. Cancer Res 77:2488-2499|
|Mayer, Ingrid A; Abramson, Vandana G; Formisano, Luigi et al. (2017) A Phase Ib Study of Alpelisib (BYL719), a PI3K?-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer. Clin Cancer Res 23:26-34|
|Jovanovi?, Bojana; Mayer, Ingrid A; Mayer, Erica L et al. (2017) A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Clin Cancer Res 23:4035-4045|
|Hanker, Ariella B; Garrett, Joan T; Estrada, Mónica Valeria et al. (2017) HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2. Clin Cancer Res 23:4323-4334|
|Morrison Joly, Meghan; Williams, Michelle M; Hicks, Donna J et al. (2017) Two distinct mTORC2-dependent pathways converge on Rac1 to drive breast cancer metastasis. Breast Cancer Res 19:74|
|Lee, Kyung-Min; Giltnane, Jennifer M; Balko, Justin M et al. (2017) MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation. Cell Metab 26:633-647.e7|
|Guerrero-Zotano, Angel L; Arteaga, Carlos L (2017) Neoadjuvant Trials in ER+ Breast Cancer: A Tool for Acceleration of Drug Development and Discovery. Cancer Discov 7:561-574|
Showing the most recent 10 out of 327 publications